



(51) International Patent Classification:

C07D 403/12 (2006.01) A61K 31/517 (2006.01)
C07D 401/14 (2006.01) A61P 35/00 (2006.01)
C07D 403/14 (2006.01) A61P 37/00 (2006.01)
C07D 473/34 (2006.01) A61P 25/28 (2006.01)
C07D 487/04 (2006.01) A61P 3/08 (2006.01)
C07D 513/04 (2006.01) A61P 9/10 (2006.01)

(21) International Application Number:

PCT/US2015/035126

(22) International Filing Date:

10 June 2015 (10.06.2015)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/012,172 13 June 2014 (13.06.2014) US

(71) Applicant: GILEAD SCIENCES, INC. [US/US]; 333 Lakeside Drive, Foster City, CA 94404 (US).

(72) Inventors: CAI, Shaopei; 3240 29th Avenue W., Seattle, WA 98199 (US). DU, Zhimin; C/o Gilead Sciences, Inc., 333 Lakeside Drive, Foster City, CA 94404 (US). KIM, Musong; C/o Gilead Sciences, Inc., 333 Lakeside Drive, Foster City, CA 94404 (US). LOYER-DREW, Jennifer, A.; C/o Gilead Sciences, Inc., 333 Lakeside Drive, Foster City, CA 94404 (US). NADUTHAMBI, Devan; C/o Gilead Sciences, Inc., 333 Lakeside Drive, Foster City, CA 94404 (US). PATEL, Leena; C/o Gilead Sciences, Inc., 333 Lakeside Drive, Foster City, CA 94404 (US). PHILLIPS, Barton, W.; C/o Gilead Sciences, Inc., 333 Lakeside Drive, Foster City, CA 94404 (US). PHILLIPS,

Gary; C/o Gilead Sciences, Inc., 333 Lakeside Drive, Foster City, CA 94404 (US). STEVENS, Kirk, L.; C/o Gilead Sciences, Inc., 333 Lakeside Drive, Foster City, CA 94404 (US). TREIBERG, Jennifer, Anne; C/o Gilead Sciences, Inc., 333 Lakeside Drive, Foster City, CA 94404 (US). VAN VELDHUIZEN, Joshua; C/o Gilead Sciences, Inc., 333 Lakeside Drive, Foster City, CA 94404 (US). WATKINS, William, J.; C/o Gilead Sciences, Inc., 333 Lakeside Drive, Foster City, CA 94404 (US). YEUNG, Suet, Chung; C/o Gilead Sciences, Inc., 333 Lakeside Drive, Foster City, CA 94404 (US).


(74) Agents: HARTRUM, J., Elin et al.; Gilead Sciences, Inc., 333 Lakeside Drive, Foster City, CA 94404 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK,

[Continued on next page]

(54) Title: PHOSPHATIDYLINOSITOL 3-KINASE INHIBITORS



(J),

(57) Abstract: The present application provides the compounds of formula (J), or pharmaceutically acceptable salts, isomers, tautomer, or a mixture thereof, wherein n, W, A', B', R^1 , R^2 , and R^3 are described herein. The compounds are inhibitors to the activities of phosphatidylinositol 3-kinase (PI3K) and are useful for treating conditions mediated by one or more PI3K isoforms. The present application further provides pharmaceutical compositions that include a compound of formula (I), or pharmaceutically acceptable salts, isomers, tautomer, or mixture thereof, and methods of using these compounds and compositions for treating conditions mediated by one or more PI3K isoforms.



SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ,
GW, KM, ML, MR, NE, SN, TD, TG).

— *as to the applicant's entitlement to claim the priority of
the earlier application (Rule 4.17(iii))*

Declarations under Rule 4.17:

— *as to applicant's entitlement to apply for and be granted
a patent (Rule 4.17(ii))*

Published:

— *with international search report (Art. 21(3))*